Optimal assessment of response in ovarian cancer

Annals of Oncology

Volumn 22, Issue SUPPL.8, 2011, Pages 49-51

  Eisenhauer, E A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

CA125; GCIG; Ovarian cancer; RECIST; Response

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; EPIRUBICIN; GEMCITABINE; TOPOTECAN; ANTINEOPLASTIC AGENT;

ANTIGEN DETECTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESEARCH; CANCER SCREENING; CANCER SURVIVAL; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; HUMAN; OVARY CANCER; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; BLOOD; DISEASE COURSE; DRUG EFFECT; FEMALE; OVARY TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84857405773     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr467     Document Type: Conference Paper

References (21)

1. Paesmans M, Sculier JP, Libert P et al. Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung Cancer Working Party. Eur J Cancer 1997; 33: 2326-2332.
2. Buyse M, Thirion P, Carlson RW et al. Relation between tumor response to firstline chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-analysis Group in Cancer. Lancet 2000; 356: 373-378.
3. Goffin J, Baral S, Tu D et al. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res 2005; 15: 5928-5934.
4. El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.J Clin Oncol 2008; 10: 1346-1354.
5. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
6. Rustin GJ, Quinn M, Thigpen T et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004;96: 487-488.
7. Vergote I, Rustin GJ, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Gynecologic Cancer InterGroup. J Natl Cancer Inst 2000; 92: 1534-1535.
8. Rustin GJ, Vergote I, Eisenhauer E et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer InterGroup (GCIG). Int J Gynecol Cancer 2011; 21:419-423.
9. Rustin GJ, van der Burg ME, Griffin CL et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010; 376: 1155-1163.
10. Bookman MA, Brady MF, McGuire WP et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol 2009; 27: 1419-1425.
11. du Bois A, Herrstedt J, Hardy-Bessard AC et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol 2010; 28: 4162-4169.
12. Hoskins P, Vergote I, Cervantes A et al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst 2010; 102: 1547-1556.
13. Cannistra SA, Matulonis UA, Penson RT. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer [erratum appears in J Clin Oncol 2008; 26: 1773]. J Clin Oncol 2007; 25: 5180-5186.
14. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007; 25: 5165-5171.
15. Perren T, Swart AM, Pfisterer J et al. on behalf of GCIG ICON7 collaborators.ICON7: A phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Ann Oncol 2010;21 (Suppl 8): viii2 (LBA 4).
16. Burger RA, Brady MF, Bookman MA et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010; 28 (Suppl 18): 946s (LBA1).
17. Rustin GJ, Nelstrop AE, Bentzen SM et al. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 2000; 18: 1733-1739.
18. Vermorken JB, Parmar MK, Brady MF et al. Clinical trials in ovarian carcinoma:study methodology. Ann Oncol 2005; 16 (Suppl 8): viii20-viii29.
19. Bast RC, Thigpen JT, Arbuck SG et al. Clinical trial endpoints in ovarian cancer:report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol 2007; 107:173-176.
20. Buyse M, Sargent DJ, Grothey A et al. Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 2010; 7: 309-317.
21. Ocaña A, Amir E, Vera F et al. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011; 29: 254-256.